Results 81 to 90 of about 52,371 (280)

Dynamic risk stratification using early CAR‐T expansion in R/R LBCL treated with axicabtagene ciloleucel

British Journal of Haematology, EarlyView.
Higher chimeric antigen receptor‐T expansion at day 7 is associated with improved progression‐free survival but also increased toxicity in axi‐cel treated patients with R/R large B‐cell lymphoma, independent of other baseline patient and disease characteristics.
Brydon Panozzo, Samuel Robinson, Adrian G. Minson, Jian Li, Kylie Baldwin, Hamish W. Scott, Jane Oliaro, Aaron J. N. Wong, Samantha van der Linde, Nicole L. O'Leary, Philip A. Thompson, John F. Seymour, Mary Ann Anderson, Constantine S. Tam, Simon J. Harrison, Michael J. Dickinson, David A. Westerman, Mark R. Dowling   +17 more
wiley   +1 more source

Immunohistochemical analysis of EBI3 expression in BL, BL/DLBCL and DLBCL.

, 2013
Sections from a case of BL (a), 2 cases of BL/DLBCL (b, c), and 2 cases of DLBCL (d, e) with or without c-myc translocation as indicated on each figure, were analyzed for EBI3 expression by immunohistochemistry.
Jean-Michel Picquenot (344706), Christian Bastard (344705), Isabelle Radford-Weiss (344707), Nicole Brousse (44590), Julie Gonin (344703), Jérôme Couturier (81165), Marie-Cécile Vacher-Lavenu (344709), Frédérique Larousserie (344704), Céline Dietrich (344708), Odile Devergne (344710)   +9 more
core   +1 more source

A phase IIa study of the anti‐PD‐L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL‐T trial

British Journal of Haematology, EarlyView.
The AVAIL‐T study, the first evaluation of programmed death ligand 1 (PD‐L1) blockade in relapsed/refractory peripheral T‐cell lymphomas (PTCL), demonstrated limited single agent activity with durable responses seen in a minority. Circulating tumour DNA revealed distinct mutational dynamics and mass cytometry identified perturbed T‐cell subsets ...
Matthew J. Ahearne, Matthew A. Timmins, Charlotte Gaskell, Aimee Jackson, Clare Morland, Sonia Fox, Louise Hopkins, Nadia Nawaz, Susann Lehmann, Marc Wadsley, Caroline Cowley, Jacqueline Shaw, Naeem Khan, Nagesh Kalakonda, Christopher Trethewey, Ram Malladi, Paul Fields, Dima El Sharkawi, Michael Quinn, Nimish Shah, Andrew Davies, Kim Linton, Pam McKay, Rod Johnson, Simon D. Wagner, David Lewis, Graham P. Collins, Christopher P. Fox, Kate Cwynarski   +28 more
wiley   +1 more source

A Large Room for Improvement in the Management of Relapsed/ Refractory Large B-Cell Lymphoma in Türkiye: Real-World Outcomes in a Setting Without Access to T-Cell Redirecting Therapies

Turkish Journal of Hematology
Objective: Patients with large B-cell lymphoma (LBCL) who are relapsed/refractory (R/R) after frontline therapy have traditionally experienced highly unfavorable outcomes.
Umut Yılmaz, Mehmet Sinan Dal, Turgay Ulaş, Elif Birtaş Ateşoğlu, Fatma Keklik Karadağ, Meral Uluköylü Mengüç, Esra Terzi Demirsoy, Simge Erdem, Ebru Pekgüç, Taner Tan, Uğur Hatipoğlu, Eda Nuhoğlu Kantarcı, Merve Apaydın Kayer, Ahmet Bahadır Ak, Serdar Örnek, Ali Durdu, Abdulkadir Şahin, Emre Osmanbaşoğlu, Nazik Okumuş, Tuğba Zorlu, Mert Seyhan, Mustafa Murat Özbalak, Tuğrul Elverdi, Asu Fergün Yılmaz, Derya Demir, Deniz Gören, Sinem Civriz Bozdağ, Tayfur Toptaş, Işık Atagündüz, Mustafa Nuri Yenerel, Olga Meltem Akay, Öner Doğan, Muhlis Cem Ar, Özgür Mehtap, Güray Saydam, Fevzi Altuntaş, Burhan Ferhanoğlu   +36 more
doaj   +1 more source

CAR‐HEMATOTOX score to predict risk of poor outcomes with odronextamab in heavily pretreated B‐cell non‐Hodgkin lymphoma

British Journal of Haematology, EarlyView.
High versus low baseline CAR‐HEMATOTOX scores were associated with poorer safety and efficacy outcomes in patients with R/R B‐NHL who received odronextamab in the ELM‐1 and ELM‐2 studies. The CAR‐HEMATOTOX score may provide a readily available measure for identifying patients at risk of inferior clinical outcomes with odronextamab treatment.
Matthew Matasar, David Tucker, Tae Min Kim, Yuan Cheng, Jingjin Li, Saleem Shariff, Hesham Mohamed, Manjusha Namuduri, Aafia Chaudhry, Stefano Luminari   +9 more
wiley   +1 more source

The Heatmap of the gene markers for DLBCL data.

, 2014
The Heatmap describe the expression levels of the three down-regulated gene markers for DLBCL and FL type in DLBCL data.
Anirban Mukhopadhyay (169006), Monalisa Mandal (535021)   +1 more
core   +1 more source

Ibrutinib and standard immunochemotherapy in younger, high‐risk patients with diffuse large B‐cell lymphoma: A phase II study of GLA

British Journal of Haematology, EarlyView.
Summary Younger patients with high‐risk diffuse large B‐cell lymphoma (DLBCL) frequently have unfavourable outcomes. We conducted a prospective phase II study evaluating ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R‐CHOEP+I) in patients aged 18–60 years with DLBCL and age‐adjusted international prognostic index ≥2.
Evgenii Shumilov, Marita Ziepert, Birte Friedrichs, Susanne Ghandili, Kai Wille, Bertram Glass, Maike Nickelsen, Peter Borchmann, Andreas Viardot, Andrea Kerkhoff, Philipp Berning, Sebastian Böttcher, Stefan Wirths, Tobias Kewitz, Mathias Hänel, Judith Dierlamm, Andreas Rosenwald, Bettina Altmann, Georg Lenz, Norbert Schmitz   +19 more
wiley   +1 more source

Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL [PDF]

Diffuse large B cell lymphoma of activated B cell type (ABC-DLBCL), a major cell-of-origin DLBCL subtype, is characterized by chronic active B cell receptor (BCR) signaling and NF-κB activation, which can be explained by activating mutations of the BCR ...
Kupcova, K., Groen, R.A.L. de, Bergen, C.A.M. van, Yáñez, J.H.S., Koning, Marvyn T., van Bergen, Cornelis A. M., Sepulveda Yañez, Julieta Haydee, Jumaa, Hassan, Vermaat, Joost S. P., Jong, D. de, Navarrete Signorile, Marcelo Alejandro, Quinten, Edwin, Havranek, O., de Groen, Ruben A. L., Janssen, Jurriaan, Vermaat, J.S.P., de Jong, Daphne, Quinten, E., Cleven, Arjen, Havranek, Ondrej, Navarrete, M.A., Cleven, A., Veelken, Hendrik, Eken, J.A., Ylstra, Bauke, Koning, M.T., Kupcova, Kristyna, Ylstra, B., Jumaa, H., Veelken, H., Eken, Janneke A., Janssen, J.   +31 more
core   +1 more source

Whole‐genome and transcriptome analysis in relapsed/refractory non‐Hodgkin lymphoma: Results from a multicentre precision oncology cohort

British Journal of Haematology, EarlyView.
Summary Comprehensive genome and transcriptome profiling can inform the diagnosis, prognosis and management of relapsed/refractory (R/R) solid malignancies, yet its integration into clinical care has lagged despite strong biological rationale. We evaluated the clinical utility of whole genome and transcriptome analysis (WGTA) in 65 patients (37 ...
Kathleen Wee, Eric J. Zhao, Cassidy Clemente‐Jones, Rebecca J. Deyell, Shahrad R. Rassekh, Anita Villani, Rosemarie Venier, Daniel Sinnett, Sylvie Langlois, Thai Hoa Tran, Thomas Sontag, Stephanie Grover, Scott Davidson, Nisha Kanwar, Winnie Lo, Erin Pleasance, Laura Williamson, Yaoqing Shen, Alina S. Gerrie, Kerry J. Savage, Laurie H. Sehn, Christopher P. Venner, Marco A. Marra, Janessa Laskin, Diego Villa   +24 more
wiley   +1 more source

Pleiotropic Roles of FBXO11 in Tumorigenesis: Implications for Targeted Therapy

Cancer Science, EarlyView.
This complex comprises of scaffold CUL1, SKP1, RBX1 and FBXO11 receptor. The substrate is phosphorylated by specific kinase enzyme and recognized by the substrate recognition domain. FBXO11 targets numerous substrates for ubiquitination and degradation, FBXO11 substrates mainly include Snail, ZEB1, p53, BCL6, CDT2, CIITA, Cdc25a, hnRNPA2B1, SAMD1 and ...
Yuqi Zhang, Changyi Fan, Shiheng Chen, Tianyue Lu, Yuanyuan Li, Feng Du, Shanshan Wang   +6 more
wiley   +1 more source